Metronomic chemotherapy from rationale to clinical studies: A dream or reality?

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 1, 2015, Pages 46-61

  Gnoni, Antonio ^a   Silvestris, Nicola ^b   Licchetta, Antonella ^a   Santini, Daniele ^c   Scartozzi, Mario ^d   Ria, Roberto ^e   Pisconti, Salvatore ^a   Petrelli, Fausto ^f   Vacca, Angelo ^e   Lorusso, Vito ^b  

^a Moscati General Hospital   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^f TREVIGLIO HOSPITAL   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Chemo switching; Cyclophosphamide; Immunity; Maintenance; Metronomic chemotherapy; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; METHOTREXATE; NAVELBINE; SORAFENIB; TEMOZOLOMIDE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESISTANCE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CONCEPTUAL FRAMEWORK; DIARRHEA; DRUG TARGETING; FATIGUE; FUNCTIONAL STATUS; GLIOBLASTOMA; HUMAN; HYPERTENSION; IMMUNOSTIMULATION; KIDNEY CANCER; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MELANOMA; METRONOMIC DRUG ADMINISTRATION; MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; OVARY CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR VASCULARIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PRECLINICAL STUDY; VASCULARIZATION;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNITY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84930821569     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.01.008     Document Type: Review

References (124)

1. Takimoto C.H. Maximum tolerated dose: clinical endpoint for a bygone era?. Target Oncol 2009, 4(2):143-147.
2. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
3. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
4. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2007, 105:1045-1047.
5. Sarmiento R., Gasparini G. Antiangiogenic metronomic chemotherapy. Onkologie 2008, 31:161-162.
6. Paez-Ribes M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
7. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
8. Ng S.S., Figg W.D. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biol Ther 2004, 3(12):1212-1213.
9. Bocci G., Loupakis F. The possible role of chemotherapy in antiangiogenic drug resistance. Med Hypotheses 2012, 78(5):646-648.
10. Daenen L.G., Shaked Y., Man S., Xu P., Voest E.E., Hoffman R.M., et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009, 8(10):2872-2881.
11. Motegi K., Harada K., Pazouki S., Baillie R., Schor A.M. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. Histochem J 2002, 34(8-9):411-421.
12. Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003, 100:12917-12922.
13. Damber J.E., Vallbo C., Albertsson P., Lennernäs B., Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006, 58:354-360.
14. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J., et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000, 60(2):490-498.
15. Chu L.Y., Ramakrishnan D.P., Silverstein R.L. Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood 2013, 122(10):1822-1832.
16. Tsuchida R., Osawa T., Wang F., Nishii R., Das B., Tsuchida S., et al. BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. Oncogene 2013, 10.1038/onc.2013.358.
17. Tas F., Duranyildiz D., Soydinc H.O., Cicin I., Selam M., Uygun K., et al. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol 2008, 61(5):721-725.
18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
19. Browder T., Butterfield C.E., Kräling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
20. Fontana A., Falcone A., Derosa L., Di Desidero T., Danesi R., Bocci G. Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?. Drugs Aging 2010, 27(9):689-696.
21. Jurado Garcia J.M., Sánchez A., Pajares B., Pérez E., Alonso L., Alba E. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008, 10:583-586.
22. Reardon D.A., Desjardins A., Vredenburgh J.J., Gururangan S., Sampson J.H., Sathornsumetee S., et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009, 101:1986-1994.
23. Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol 2001, 2(12):733-740.
24. Drevs J., Fakler J., Eisele S., Medinger M., Bing G., Esser N., et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24(3a):1759-1763.
25. Naumov G.N., Bender E., Zurakowski D., Kang S.Y., Sampson D., Flynn E., et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006, 98(5):316-325.
26. Moserle L., Amadori A., Indraccolo S. The angiogenic switch: implications in the regulation of tumor dormancy. Curr Mol Med 2009, 9(8):935-941.
27. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
28. Stoelting S., Trefzer T., Kisro J., Steinke A., Wagner T., Peters S.O. Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 2008, 22(6):831-836.
29. Scharovsky O.G., Mainetti L.E., Rozados V.R. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 2009, 16(2):7-15.
30. Calleri A., Bono A., Bagnardi V., Quarna J., Mancuso P., Rabascio C., et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009, 15(24):7652-7657.
31. Twardowski P.W., Smith-Powell L., Carroll M., VanBalgooy J., Ruel C., Frankel P., et al. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest 2008, 26(1):53-59.
32. Laquente B., Vinals F., Germa J.R. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 2007, 9:93-98.
33. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
34. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
35. Hoenicke L., Zender L. Immune surveillance of senescent cells-biological significance in cancer- and non-cancer pathologies. Carcinogenesis 2012, 33(6):1123-1126.
36. Terme M., Colussi O., Marcheteau E., Tanchot C., Tartour E., Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012, 2012:492920.
37. Poschke I., Mougiakakos D., Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011, 60(8):1161-1171.
38. Kosmaczewska A., Ciszak L., Potoczek S., Frydecka I. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp 2008, 56:181-191.
39. Kono K., et al. CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006, 55:1064-1071.
40. Ghiringhelli F., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344.
41. Loeffler M., Kruger J.A., Reisfeld R.A. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 2005, 65:5027-5030.
42. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
43. Banissi C., Ghiringhelli F., Chen L., Carpentier A.F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009, 58:1627-1634.
44. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56:641-648.
45. Tanaka H., Matsushima H., Mizumoto N., Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res 2009, 69:6978-6986.
46. Udagawa T. Tumor dormancy of primary and secondary cancers. APMIS 2008, 116:615-628.
47. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004, 10:8152-8162.
48. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846.
49. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136(2):261-276.
50. Naumov G.N., Akslen L.A., Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006, 5(16):1779-1787.
51. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 2001, 11:285-295.
52. Mahnke Y.D., Schwendemann J., Beckhove P., Schirrmacher V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 2005, 115:325-336.
53. Andre N., Pasquier E. Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nat Clin Pract Oncol 2009, 6:E1.
54. Seruga B., Tannock I.F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008, 5:574-576.
55. Cabral F.R. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 1983, 97:22-29.
56. Yang C.P., et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 2005, 4:987-995.
57. Sterba J., et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 2006, 29:308-313.
58. Wu H., Xin Y., Zhao J., Sun D., Li W., Hu Y., et al. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol 2011, 68(4):879-887.
59. Penel N., Adenis A., Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?. Crit Rev Oncol Hematol 2012, 82(1):40-50. 10.1016/j.critrevonc.2011.04.009.
60. Bertolini F., Mancuso P., Shaked Y., Kerbel R.S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discovery Today 2007, 12:806-812.
61. Calvani N., Orlando L., Nacci A., Sponziello F., Cinefra M., Cinieri S. Metronomic chemotherapy against cancer: from paradigm to clinical practice?. Tumori 2009, 95(Nov-Dec (6)):843-845.
62. Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999, 94(12):4143-4155.
63. Ribatti D., Guidolin D., Conconi M.T., Nico B., Baiguera S., Parnigotto P.P., et al. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 2003, 22(Sep (41)):6458-6461.
64. Hashimoto K., Man S., Xu P., Cruz-Munoz W., Tang T., Kumar R., et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010, 9(4):996-1006.
65. Merritt W.M., Nick A.M., Carroll A.R., Lu C., Matsuo K., Dumble M., et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 2010, 9(4):985-995. (996-1006).
66. Aljuffali I.A., Mock J.N., Costyn L.J., Nguyen H., Nagy T., Cummings B.S., et al. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. Cancer Biol Ther 2011, 12(5):407-420.
67. Addeo R., Sgambato A., Cennamo G., Montella L., Faiola V., Abbruzzese A., et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 2010, 10(Aug (4)):301-306.
68. Cazzaniga M.E., Torri V., Villa F., Giuntini N., Riva F., Zeppellini A., et al. Efficacy and safety of the all oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study. Int J Breast Cancer 2014, 2014:769790.
69. Pluma Jmenez M.A., Perez M., Bautista Aragon Y.L., Villalobos R., Rivera S., Ortiz K., et al. Oral metronomic administration of cyclophosphamide and vinorelbine in previously treated patients with metastatic breast cancer: Phase II trial. J Clin Oncol 2011, 29. [suppl; abstr e11017].
70. Fedele P., Marino A., Orlando L., Schiavone P., Nacci A., Sponziello F., et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 2012, 48(1):24-29.
71. Schwartzberg L.S., Wang G., Somer B.G., Blakely L.J., Wheeler B.M., Walker M.S., et al. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Breast Cancer 2013, (13):S1526-S8209. (00216-4).
72. Munzone E., Di Pietro A., Goldhirsch A., Minchella I., Verri E., Cossu Rocca M., et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast 2010, 19(Feb (1)):33-37.
73. Gebbia V., Boussen H., Valerio M.R. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res 2012, 32(2):529-536.
74. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26:4899-4905.
75. Orlando L., Cardillo A., Ghisini R., Rocca A., Balduzzi A., Torrisi R., et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006, 6:225.
76. Colleoni M., Orlando L., Sanna G., Rocca A., Maisonneuve P., Peruzzotti G., et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006, 17:232-238.
77. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26(Jan (2)):242-245.
78. Millikan R., Thall P.F., Lee S.J., Jones D., Cannon M.W., Kuebler J.P., et al. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 2003, 21(Mar (5)):878-883.
79. Jellvert A., Lissbrant I.F., Edgren M., Ovferholm E., Braide K., Olvenmark A.M., et al. Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med 2011, 2(Jul (4)):579-584. (Epub 2011 May 12).
80. Gebbia V., Serretta V., Borsellino N., Valerio M.R. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology 2011, 78(Nov (5)):1125-1130. GSTU Foundation. 10.1016/j.urology.2011.08.010.
81. Khan O.A., Blann A.D., Payne M.J., Middleton M.R., Protheroe A.S., Talbot D.C., et al. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 2011, 104(Jun (12)):1822-1827. (Epub 2011 May 17). 10.1038/bjc.2011.154.
82. Zhou M., Yu P., Qu X., Liu Y., Zhang J. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS ONE 2013, 8(12):e81858. 10.1371/journal.pone.0081858.
83. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26(1):76-82. 10.1200/JCO.2007.12.1939.
84. Eichbaum M., Mayer C., Eickhoff R., Bischofs E., Gebauer G., Fehm T., et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 2011, Oct (11):453. 10.1186/1471-2407-11-453.
85. Molina A.M., Motzer R.J., Heng D.Y. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol 2013, 40(Aug (4)):436-443.
86. Bellmunt J., Trigo J.M., Calvo E., Carles J., Pérez-Gracia J.L., Rubió J., et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010, 11(4):350-357. (Epub 2010 Feb 15). 10.1016/S1470-2045(09)70383-3.
87. Huijts C.M., Santegoets S.J., van den Eertwegh A.J., Pijpers L.S., Haanen J.B., de Gruijl T.D., et al. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011, 11:505. 10.1186/1471-2407-11-505.
88. Stockhammer F., Misch M., Koch A., Czabanka M., Plotkin M., Blechschmidt C., et al. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 2010, 100(Dec (3)):407-415. (Epub 2010 May 6). 10.1007/s11060-010-0192-y.
89. Chowdhary S., Chamberlain M. Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother 2013, 13(8):937-949.
90. Desjardins A., Reardon D.A., Coan A., Marcello J., Herndon J.E., Bailey L., et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012, 118(5):1302-1312.
91. Reardon D.A., Desjardins A., Peters K., Gururangan S., Sampson J., Rich J.N., et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011, 103(Jun (2)):371-379.
92. Zustovich F., Landi L., Lombardi G., Porta C., Galli L., Fontana A., et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 2013, 33(8):3487-3494.
93. Del Conte A., Saracchini S., Santeufemia D.A., Lo Re G. Pilot single institutional experience on tolerance and clinical efficacy of metronomic chemotherapy with oral vinorelbine in unfit patients with advanced or metastatic non-small cell lung cancer (NSCLC). Tumori 2011, [Abstract D55 (Session D].
94. Briasoulis E., Aravantinos G., Kouvatseas G., Pappas P., Biziota E., Sainis I., et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 2013, 13(May (1)):263.
95. Correale P., Botta C., Basile A., Pagliuchi M., Licchetta A., Martellucci I., et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2011, 12(Jul (2)):112-118.
96. He S., Shen J., Hong L., Niu L., Niu D. Capecitabine metronomic chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol 2012, 29(Mar (1)):100-106.
97. Carreca I.U., Bellomo F.M., Pernice G., Antista M., Amelio R., Balducci L. Metronomic (M), capecitabine (C), and oxaliplatin (O) plus bevacizumab (B) as treatment of advanced colorectal cancer (ACRC) in very elderly people (M-COB): Efficacy and safety (E&S) evaluation-A 2-year monitoring. J Clin Oncol 2011, 29. [suppl; abstr e14086].
98. Kelley R.K., Hwang J., Magbanua M.J., Watt L., Beumer J.H., Christner S.M., et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer 2013, 109(Oct (7)):1725-1734.
99. Lin P.C., Chen W.S., Chao T.C., Yang S.H., Tiu C.M., Liu J.H. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol 2007, 60(Aug (3)):351-356. (Epub 2006 Nov 17).
100. Koopman M., Simkens L., May A.M., Mol L., van Tinteren H., Punt C.J.A. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine+bevacizumab versus observation after induction treatment with chemotherapy+bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014, 32(5s). [suppl; abstr 3504].
101. Arnold D., Graeven U., Lerchenmuller C.A., Killing B., Depenbusch R., Steffens C.C., et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207). J Clin Oncol 2014, 32(5s). (suppl; abstr 3503).
102. Villanueva A., Hernandez-Gea V., Llovet J.M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013, 10(1):34-42.
103. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(Jul (4)):378-390. SHARP Investigators Study Group.
104. Brandi G., de Rosa F., Bolondi L., Agostini V., Di Girolamo S., Nobili E., et al. Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori 2010, 96(Nov-Dec (6)):1028-1030.
105. Brandi G., De Rosa F., Agostini V., Di Girolamo S., Andreone P., Bolondi L., et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a Phase II study. Oncologist 2013, 18:1256-1257. for the Italian Liver Cancer (ITA.LI.CA) Group.
106. Botti G., Cerrone M., Scognamiglio G., Anniciello A., Ascierto P.A., Cantile M. Microenvironment and tumor progression of melanoma: new therapeutic prospectives. J Immunotoxicol 2013, 10(Jul-Sep (3)):235-252.
107. Corti A. Chromogranin A and the tumor microenvironment. Cell Mol Neurobiol 2010, 30(Nov (8)):1163-1170.
108. Vacca A., Ribatti D. Angiogenesis and vasculogenesis in multiple myeloma: role of inflammatory cells. Recent Results Cancer Res 2011, 183:87-95.
109. Müller-Decker K. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev 2011, 30(Dec (3-4)):343-361.
110. Nikolaou V., Stratigos A., Bafaloukos D., Katsambas A. Antiangiogenic and antiapoptotic treatment in advanced melanoma. Clin Dermatol 2013, 31(May-Jun (3)):257-263.
111. Khan Z., Khan N., Tiwari R.P., Sah N.K., Prasad G.B., Bisen P.S. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 2011, 12(Jun (7)):1082-1093.
112. Bhatt R.S., Merchan J., Parker R., Wu H.K., Zhang L., Seery V., et al. A phase 2 pilot trial of low-dose, continuous infusion, or metronomic paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010, 116(Apr (7)):1751-1756. 10.1002/cncr.24902.
113. Borne E., Desmedt E., Duhamel A., Mirabel X., Dziwniel V., Maire C., et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 2010, 28(Oct (5)):684-689.
114. Koumarianou A., Antoniou S., Kanakis G., Economopoulos N., Rontogianni D., Ntavatzikos A., et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer 2012, 19(1):L1-L4.
115. Zhou F., Guo L., Shi H., Lin C., Hou J. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 2010, 10:51-55.
116. Suvannasankha A., Fausel C., Juliar B.E., et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007, 12:99-106.
117. Papanikolaou X., Szymonifka J., Rosenthal A., Heuck C.J., Mitchell A., Johann D., et al. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica 2013, 98(7).
118. Mross K., Steinbild S. Metronomic anti-cancer therapy-an ongoing treatment option for advanced cancer patients. J Cancer Ther Res 2012, 1:32.
119. Korantzis I., Kalogeras K.T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel. Anticancer Res 2012, 32(10):4569-4580.
120. Lansiaux A., Salingue S., Dewitte A., Clisant S., Penel N. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. Invest New Drugs 2012, 30(Feb (1)):403-404.
121. Miscoria M., Tonetto F., Deroma L., Machin P., Di Loreto C., Driol P., et al. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. Anticancer Drugs 2012, 23(3):326-334.
122. Orlandi P., Fontana A., Fioravanti A., Di Desidero T., Galli L., Derosa L., et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer 2013, 109(Aug (4)):957-964.
123. Ribatti D., Nico B., Crivellato E., Vacca A. The structure of the vascular network of tumors. Cancer Lett 2007, 248(Apr (1)):18-23.
124. Hida K., Ohga N., Akiyama K., Maishi N., Hida Y. Heterogeneity of tumor endothelial cells. Cancer Sci 2013, (Aug). 10.1111/cas.12251.